170 related articles for article (PubMed ID: 35460379)
1. Tcf-1 protects anti-tumor TCR-engineered CD8
Zangari B; Tsuji T; Matsuzaki J; Mohammadpour H; Eppolito C; Battaglia S; Ito F; Chodon T; Koya R; Robert McGray AJ; Odunsi K
Cancer Immunol Immunother; 2022 Dec; 71(12):2881-2898. PubMed ID: 35460379
[TBL] [Abstract][Full Text] [Related]
2. A rare population of tumor antigen-specific CD4
Matsuzaki J; Tsuji T; Chodon T; Ryan C; Koya RC; Odunsi K
J Immunother Cancer; 2019 Jan; 7(1):7. PubMed ID: 30626427
[TBL] [Abstract][Full Text] [Related]
3. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
4. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
5. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.
Shang XY; Chen HS; Zhang HG; Pang XW; Qiao H; Peng JR; Qin LL; Fei R; Mei MH; Leng XS; Gnjatic S; Ritter G; Simpson AJ; Old LJ; Chen WF
Clin Cancer Res; 2004 Oct; 10(20):6946-55. PubMed ID: 15501973
[TBL] [Abstract][Full Text] [Related]
6. Antigen-presenting B cells promote TCF-1
Hou D; Wan H; Katz JL; Wang S; Castro BA; Vazquez-Cervantes GI; Arrieta VA; Dhiantravan S; Najem H; Rashidi A; Chia TY; Arjmandi T; Collado J; Billingham L; Lopez-Rosas A; Han Y; Sonabend AM; Heimberger AB; Zhang P; Miska J; Lee-Chang C
Front Immunol; 2023; 14():1295218. PubMed ID: 38268923
[TBL] [Abstract][Full Text] [Related]
7. Generation and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1
Shenderov E; Kandasamy M; Gileadi U; Chen J; Shepherd D; Gibbs J; Prota G; Silk JD; Yewdell JW; Cerundolo V
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088742
[TBL] [Abstract][Full Text] [Related]
8. TCF-1 regulates NKG2D expression on CD8 T cells during anti-tumor responses.
Harris R; Mammadli M; Hiner S; Suo L; Yang Q; Sen JM; Karimi M
Cancer Immunol Immunother; 2023 Jun; 72(6):1581-1601. PubMed ID: 36562825
[TBL] [Abstract][Full Text] [Related]
9. Role of TCF-1 in differentiation, exhaustion, and memory of CD8
Zhang J; Lyu T; Cao Y; Feng H
FASEB J; 2021 May; 35(5):e21549. PubMed ID: 33913198
[TBL] [Abstract][Full Text] [Related]
10. Human naive CD8 T cells down-regulate expression of the WNT pathway transcription factors lymphoid enhancer binding factor 1 and transcription factor 7 (T cell factor-1) following antigen encounter in vitro and in vivo.
Willinger T; Freeman T; Herbert M; Hasegawa H; McMichael AJ; Callan MF
J Immunol; 2006 Feb; 176(3):1439-46. PubMed ID: 16424171
[TBL] [Abstract][Full Text] [Related]
11. Differentiation and persistence of memory CD8(+) T cells depend on T cell factor 1.
Zhou X; Yu S; Zhao DM; Harty JT; Badovinac VP; Xue HH
Immunity; 2010 Aug; 33(2):229-40. PubMed ID: 20727791
[TBL] [Abstract][Full Text] [Related]
12. Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression.
Poncette L; Chen X; Lorenz FK; Blankenstein T
J Clin Invest; 2019 Jan; 129(1):324-335. PubMed ID: 30530988
[TBL] [Abstract][Full Text] [Related]
13. CD8 T cell tolerance to a tumor-associated self-antigen is reversed by CD4 T cells engineered to express the same T cell receptor.
Ghorashian S; Veliça P; Chua I; McNicol AM; Carpenter B; Holler A; Nicholson E; Ahmadi M; Zech M; Xue SA; Uckert W; Morris E; Chakraverty R; Stauss HJ
J Immunol; 2015 Feb; 194(3):1080-9. PubMed ID: 25539815
[TBL] [Abstract][Full Text] [Related]
14. Human Granzyme K Is a Feature of Innate T Cells in Blood, Tissues, and Tumors, Responding to Cytokines Rather than TCR Stimulation.
Duquette D; Harmon C; Zaborowski A; Michelet X; O'Farrelly C; Winter D; Koay HF; Lynch L
J Immunol; 2023 Aug; 211(4):633-647. PubMed ID: 37449888
[TBL] [Abstract][Full Text] [Related]
15. An engineered IL-2 partial agonist promotes CD8
Mo F; Yu Z; Li P; Oh J; Spolski R; Zhao L; Glassman CR; Yamamoto TN; Chen Y; Golebiowski FM; Hermans D; Majri-Morrison S; Picton LK; Liao W; Ren M; Zhuang X; Mitra S; Lin JX; Gattinoni L; Powell JD; Restifo NP; Garcia KC; Leonard WJ
Nature; 2021 Sep; 597(7877):544-548. PubMed ID: 34526724
[TBL] [Abstract][Full Text] [Related]
16. Sustained CD28 costimulation is required for self-renewal and differentiation of TCF-1
Humblin E; Korpas I; Lu J; Filipescu D; van der Heide V; Goldstein S; Vaidya A; Soares-Schanoski A; Casati B; Selvan ME; Gümüş ZH; Wieland A; Corrado M; Cohen-Gould L; Bernstein E; Homann D; Chipuk J; Kamphorst AO
Sci Immunol; 2023 Aug; 8(86):eadg0878. PubMed ID: 37624910
[TBL] [Abstract][Full Text] [Related]
17. TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate Decision.
Chen Z; Ji Z; Ngiow SF; Manne S; Cai Z; Huang AC; Johnson J; Staupe RP; Bengsch B; Xu C; Yu S; Kurachi M; Herati RS; Vella LA; Baxter AE; Wu JE; Khan O; Beltra JC; Giles JR; Stelekati E; McLane LM; Lau CW; Yang X; Berger SL; Vahedi G; Ji H; Wherry EJ
Immunity; 2019 Nov; 51(5):840-855.e5. PubMed ID: 31606264
[TBL] [Abstract][Full Text] [Related]
18. The Transcription Factor TCF1 Preserves the Effector Function of Exhausted CD8 T Cells During Chronic Viral Infection.
Wang Y; Hu J; Li Y; Xiao M; Wang H; Tian Q; Li Z; Tang J; Hu L; Tan Y; Zhou X; He R; Wu Y; Ye L; Yin Z; Huang Q; Xu L
Front Immunol; 2019; 10():169. PubMed ID: 30814995
[TBL] [Abstract][Full Text] [Related]
19. Human Lymph Nodes Maintain TCF-1
Miron M; Kumar BV; Meng W; Granot T; Carpenter DJ; Senda T; Chen D; Rosenfeld AM; Zhang B; Lerner H; Friedman AL; Hershberg U; Shen Y; Rahman A; Luning Prak ET; Farber DL
J Immunol; 2018 Oct; 201(7):2132-2140. PubMed ID: 30111633
[TBL] [Abstract][Full Text] [Related]
20. A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression.
Gunda V; Frederick DT; Bernasconi MJ; Wargo JA; Parangi S
Thyroid; 2014 Aug; 24(8):1241-50. PubMed ID: 24811699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
